OPM Biosciences Launched Biosimilar Optimization Platforms
The firm introduced tools to improve productivity and quality alignment for developers of biologic drug copies.
Updated on Oct. 1, 2026 in Biotech
Live Poll
Do you believe the growth in biosimilar development will make medical treatments more affordable?
OPM Biosciences has released the Biosimilar Media Optimization Service and the Sureness Biosimilar Platform. These tools are designed to assist developers in increasing output and ensuring quality consistency with reference biologics.
Why it matters
Patent expirations have accelerated the need for efficient biosimilar production that meets specific reference-product quality benchmarks. Developers now require integrated solutions to improve productivity while adhering to stringent global regulatory standards.
The OPM-CHO culture media platform demonstrated lot-to-lot variability below 5%, with an average titer improvement of 96% across 35 internal evaluations. The new service provides an 81% average titer increase across 70 projects by tuning quality attributes to match reference products.
The players
OPM Biosciences
A developer of cell culture media platforms and biomanufacturing services that has supported over 390 molecules in clinical or commercial stages.
The details
The Biosimilar Media Optimization Service uses molecule-specific media development to align critical quality attributes—the chemical and physical characteristics that ensure drug safety and efficacy—with target reference-product profiles. The Sureness Biosimilar Platform functions as an integrated framework that links this specialized media development with existing contract development and manufacturing organization capabilities. This approach aims to streamline the path from initial formulation to commercial production by coordinating media performance with regulatory requirements.
Timeline
October 1, 2026: OPM Biosciences launched the Biosimilar Media Optimization Service and Sureness Biosimilar Platform.
The Tech Race
This development extends the existing OPM-CHO cell culture media platform by layering on specialized services for the rapidly expanding biosimilar market. It positions the company to compete by integrating media formulation directly with contract manufacturing and regulatory support.
Biopharmaceutical companies can now utilize these tools to shorten production timelines and ensure their biosimilars meet the required profile of reference biologics. The service is currently available for developers targeting regulatory submissions in the U.S. and China.
The takeaway
The move signals a trend toward integrated, data-driven optimization as the primary mechanism for capturing biosimilar market share. Observers should track subsequent regulatory approvals in the U.S. and China for programs utilizing these specific platforms.
Further reading
For more on the latest research and developments in this sector, visit Biotech.
Source note: This article includes information reported by Selectscience.
Live Poll
Do you believe the growth in biosimilar development will make medical treatments more affordable?
